Analysis of p53 gene mutations in acute myeloid leukemia - PubMed (original) (raw)
Analysis of p53 gene mutations in acute myeloid leukemia
D Trecca et al. Am J Hematol. 1994 Aug.
Abstract
We have previously reported the absence of mutations within exons 5-9 of the p53 gene in a panel of 30 cases of acute promyelocytic leukemia (APL), which represent the M3 FAB type of acute myeloid leukemia (AML). In the present report, we extend our analysis of p53 gene mutations to 70 cases of AML representative of the other FAB types of the disease, including M1 (16 cases), M2 (20 cases), M4 (17 cases), M5 (12 cases), and M6 (5 cases). DNAs were analyzed for p53 gene mutations in exons 5 to 9 by polymerase chain reaction (PCR), single-strand conformation polymorphism (SSCP), and direct sequencing of PCR-amplified products. Mutant p53 alleles were detected in 5 of 70 cases; 1 case in exon 5, 2 cases in exon 6, and 2 cases in exon 7. The alterations of the p53 gene were represented by point mutation leading to an amino acid substitution in four cases, and deletion in the remaining case. In four of the five cases, direct sequencing indicated the loss of the normal p53 allele; in the remaining case, two mutations were detected, presumably involving both p53 alleles. Three cases showed mutations at diagnosis; in the remaining two, the mutations were observed in clinical relapse but not at diagnosis. Our results confirm the relatively low incidence of p53 mutations in AML and further support the evidence that p53 plays a role in leukemogenesis through a recessive mechanism (two-hit model) of inactivation of tumor suppressor activity.
Similar articles
- Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, Störkel S, Ortel J, Kolbe K, Huber C, Huhn D, Neubauer A. Seliger B, et al. Eur J Haematol. 1996 Sep;57(3):230-40. doi: 10.1111/j.1600-0609.1996.tb01369.x. Eur J Haematol. 1996. PMID: 8898928 - Mutations of the P53 gene in acute myeloid leukaemia.
Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Laï JL, Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP. Fenaux P, et al. Br J Haematol. 1992 Feb;80(2):178-83. doi: 10.1111/j.1365-2141.1992.tb08897.x. Br J Haematol. 1992. PMID: 1550773 - p53 gene mutations and loss of a chromosome 17p in Philadelphia chromosome (Ph1)-positive acute leukemia.
Nakai H, Misawa S, Tanaka S, Nishigaki H, Taniwaki M, Yokota S, Horiike S, Takashima T, Seriu T, Nakagawa H, et al. Nakai H, et al. Leukemia. 1993 Oct;7(10):1547-51. Leukemia. 1993. PMID: 8412316 - Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
Lepelley P, Preudhomme C, Vanrumbeke M, Quesnel B, Cosson A, Fenaux P. Lepelley P, et al. Leukemia. 1994 Aug;8(8):1342-9. Leukemia. 1994. PMID: 8057671 - Detection of p53 gene mutations in human leukemia by PCR-SSCP analysis and direct nucleotide sequencing.
Wang R, Yu Z, Gu J, Li D, Wang M, Cao Y. Wang R, et al. Chin Med J (Engl). 1998 Apr;111(4):339-42. Chin Med J (Engl). 1998. PMID: 10374399
Cited by
- Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia.
Abramowitz J, Neuman T, Perlman R, Ben-Yehuda D. Abramowitz J, et al. BMC Med Genomics. 2017 Mar 24;10(1):18. doi: 10.1186/s12920-017-0249-2. BMC Med Genomics. 2017. PMID: 28340577 Free PMC article. - p53 as an Effector or Inhibitor of Therapy Response.
Ablain J, Poirot B, Esnault C, Lehmann-Che J, de Thé H. Ablain J, et al. Cold Spring Harb Perspect Med. 2015 Dec 4;6(1):a026260. doi: 10.1101/cshperspect.a026260. Cold Spring Harb Perspect Med. 2015. PMID: 26637438 Free PMC article. Review. - Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity.
Wang YV, Leblanc M, Fox N, Mao JH, Tinkum KL, Krummel K, Engle D, Piwnica-Worms D, Piwnica-Worms H, Balmain A, Kaushansky K, Wahl GM. Wang YV, et al. Genes Dev. 2011 Jul 1;25(13):1426-38. doi: 10.1101/gad.2024411. Genes Dev. 2011. PMID: 21724834 Free PMC article. - MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.
Kindle KB, Troke PJ, Collins HM, Matsuda S, Bossi D, Bellodi C, Kalkhoven E, Salomoni P, Pelicci PG, Minucci S, Heery DM. Kindle KB, et al. Mol Cell Biol. 2005 Feb;25(3):988-1002. doi: 10.1128/MCB.25.3.988-1002.2005. Mol Cell Biol. 2005. PMID: 15657427 Free PMC article. - Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.
Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, Pruneri G, Viale G, Appella E, Pelicci P, Minucci S. Insinga A, et al. EMBO J. 2004 Mar 10;23(5):1144-54. doi: 10.1038/sj.emboj.7600109. Epub 2004 Feb 19. EMBO J. 2004. PMID: 14976551 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous